Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.

Response to the Combination of Stereotactic Body Radiation Therapy and Concurrent PD-1 Blockade in Patients With Metastatic Renal Cell Carcinoma: a Retrospective Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06327178

Enrollment

Registered

2024-03-25

Start date

2023-10-01

Completion date

2025-06-30

Last updated

2025-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC

Keywords

stereotactic body radiotherapy, abscopal effects, PD-1 blockade

Brief summary

Prior research has indicated that stereotactic body radiotherapy (SBRT) can effectively trigger systemic anti-tumor immune response. The goal of this observational study is to learn about abscopal effects of stereotactic body radiotherapy and concurrent anti-PD-1 antibody treatment in patients of metastatic clear renal cell carcinoma. The primary objective was to assess the objective response rate (ORR) in non-irradiated lesions, and incidence of adverse events (AEs).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age≥18 years at the time of signing informed consent; * Histologically confirmed, advanced renal cell carcinoma of stage IV (AJCC 8); * Previously received SBRT and concurrent PD-1 blockade treatment； * Evidence of measurable metastatic kidney cancer according to RECIST 1.1 criteria.

Exclusion criteria

* Patients who cannot be adequately followed up; * Has a known additional malignancy that is progressing or requires active treatment.

Design outcomes

Primary

Measure	Time frame
Objective Response Rate	Up to 2 years.

Countries

China

Contacts

Primary ContactGuozhu Xie

xieguozhu@126.com02062787693

Outcome results